The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
Research and Practice in Thrombosis and Haemostasis, 2022 Introduction Edoxaban is the only anti‐Xa inhibitor metabolized in pharmacologically active moiety that could interfere with chromogenic anti‐Xa assays, especially in case of drug‐drug interactions or physiological disorders.
Romain Siriez +9 more
doaj +2 more sources
Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. [PDF]
PLoS ONE, 2018 Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant human FXa, rapidly reverses the anticoagulation effects of direct and indirect FXa inhibitors.To evaluate
Genmin Lu +9 more
doaj +2 more sources
Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region [PDF]
Drugs in Context, 2023 Edoxaban, a once-daily, direct-acting oral anticoagulant, is approved to prevent stroke or systemic embolism in non-valvular atrial fibrillation (NVAF) and treat venous thromboembolism.
Alejandro Bimbo Diaz +8 more
doaj +2 more sources
Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
Frontiers in Pharmacology, 2021 Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations.Methods: Participants with atrial ...
Ching-Hua Kuo +2 more
exaly +3 more sources
Effect of concomitant chemotherapy on edoxaban plasma concentration in patients with colorectal cancer [PDF]
BMC GastroenterologyPurpose Direct oral anticoagulants are a treatment option for cancer-associated venous thromboembolism (VTE). In patients receiving chemotherapy for cancer, there may be pharmacokinetic drug–drug interaction between anti-cancer agents and direct oral ...
Jihyung Song +7 more
doaj +2 more sources
Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study [PDF]
Brain Sciences, 2023 Background: Little evidence is available on the long-term efficacy and safety of edoxaban, mainly due to the recent release date. The primary objective of the study was to evaluate the safety of edoxaban, defined by the incidence of major bleedings.
Irene Scala +10 more
doaj +2 more sources
The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease [PDF]
Research and Practice in Thrombosis and Haemostasis, 2020 Background Little evidence is available for treatment of pediatric venous thromboembolism (VTE). Large randomized controlled trials are challenging in children.
Cornelia Heleen vanOmmen +9 more
doaj +2 more sources
Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy [PDF]
Case Reports in Critical Care, 2016 Introduction. The main adverse effect of anticoagulant therapy is bleeding, and major bleeding, including intracranial, gastrointestinal, and retroperitoneal bleeding, has been reported as an adverse effect of edoxaban, a direct oral anticoagulant (DOAC).
Kenichi Nitta +4 more
doaj +2 more sources
Edoxaban in venous thromboembolism and stroke prevention: an appraisal [PDF]
Vascular Health and Risk Management, 2016 Marco Proietti,1,2 Gregory YH Lip1,3 1University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK; 2Department of Internal Medicine and Medical Specialties, Sapienza-University of Rome, Rome, Italy; 3Aalborg Thrombosis ...
Proietti M, Lip GYH
doaj +2 more sources
Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism [PDF]
Thrombosis JournalBackground Edoxaban, a direct oral anticoagulant (DOAC), is a first-line treatment for venous thromboembolism (VTE) and the suppression of VTE recurrence.
Masashi Yoshida +20 more
doaj +2 more sources